Cancer Statistics 2019: Cancer Death Rates Have Declined 27% In 25 Years, And We Still Have A Long Way To Go

Good news is always welcome, especially when talking about something as serious as cancer. And there is plenty of welcome information in the American Cancer Society’s release today of our annual report on “Cancer Statistics, 2019” and its accompanying consumer-oriented version of “Cancer Facts & Figures 2019.”

Among the good news in this report: A significant decline in death rates from cancer—especially among some of the most common cancers, significant improvements in early detection and treatment of cancer, and a decrease in the disparities in death rates between African-Americans and whites.

Despite the good news, unfortunately, there are also pieces of the puzzle that have not been solved. And to ignore that information is a disservice to those who struggle with cancer and those who have passed because of this dread disease. The reality is we can—indeed, we must—do better. And that fact is an equally important part of the information contained in this report.

First, the good news statistics just as they are reported:

  • The death rate from all cancers combined has declined 27% since 1991—that’s over the past 25 years for which we have accurate information–because of increased awareness, decreased smoking and advances in early detection and treatment
  • There have been substantial declines in death rates from some of the most common cancers:

There are several cancers where early detection and treatment have resulted in significant 5-year survivals:

  • 98% in prostate cancer
  • 92% in melanoma
  • 90% in breast cancer

All these numbers add up to an astounding 2.6 million—yes, MILLION—premature deaths from cancer averted over those 25 years. The impact of that reality is nothing short of remarkable in so many ways.

And then there are other important pieces of this puzzle:

  • In 2019 the American Cancer Society estimates there will be 1.762 million new cases of invasive cancer diagnosed in the United States. Stated another way: 4,800 people will be diagnosed with invasive cancer in the United States every day.
  • Sadly, in 2019, the Society estimates there will be 606,880 cancer deaths. That translates into 1,660 cancer deaths daily, or 1.2 deaths every minute, every day.
  • Your lifetime probability of hearing “you have cancer” (excluding skin cancers and non-invasive cancers) is 39.3% in men and 37.7% in women. That’s close to 4 out of every 10 people in this country, over their lives.

Yet, as mentioned, there are serious issues we must recognize and deal with if we are to continue to tilt the odds in favor folks throughout the country:

  • We are seeing the racial gap in cancer deaths is narrowing between blacks and whites—but it still exists and needs to be recognized for what it is: an inequality in care and outcomes
  • At the same time, another significant inequality is getting worse, and that’s related to socioeconomic status (SES), which includes income, education, insurance status, as well as living in rural, underserved counties throughout the country. What shows up in the statistics is that the difference in outcomes based on SES and location isn’t that great for cancers where we don’t have effective early detection and treatment. In those circumstances, outcomes are pretty much the same. However, for those cancers where those factors are proven to make a difference, there is a substantial gap with those living in cities and those in higher SES brackets doing significantly better (think breast and cervical cancers).
  • In the poorest counties in the country death rates from cervical cancer are two times higher than in other parts of the country. There are even differences within states when comparing metropolitan centers to rural communities, with those in the cities having better outcomes. All of this speaks volumes about the need to offer more available medical care and early detection, as well as making HPV vaccination available to all who are eligible nationwide. This alone would result in a rapid decline in cervical cancer deaths, which today account for 9 deaths in young women ages 20-39 every week.
  • And it’s not just cervical cancer where more deaths occur in rural counties: death rates are 40% higher for lung cancer and liver cancer as well. The incidence of lung cancer in Kentucky is 3.5 times greater in men than that in Utah. For women, the difference in death rates between the two states is 3.3 times greater in Kentucky compared to Utah.
  • Then there are the concerns about the rising rates of colorectal cancer in folks younger than 55 at about 2% per year since the mid-1990’s. That’s why the American Cancer Society recently recommended that routine screening for CRC in people at average risk be moved forward to 45 instead of the former recommendation to start at age 50.

Lung cancer is not immune to the unfortunate news:

  • Notwithstanding the significant declines in cigarette smoking, we are starting to see higher rates of lung cancer in young women compared with men born around the 1960’s—and we don’t know the reason. It does not appear to be related to smoking behaviors, which serves to point out once again that we must view lung cancer as a disease in all its manifestations.
  • And even for those we know to be at highest risk of lung cancer, the latest available information (from 2015) shows that only 4% of 6.8 million eligible Americans reported being screened for lung cancer with low-dose computed tomography—a technique that has been proven to reduce (although not eliminate) the probability of death from this disease which remains generally refractory to available treatments (although progress is certainly being made in that regard). Getting more people aware of lung cancer screening–along with educating them about the benefits and risks of the test—remains one of the opportunities and challenges for the year ahead.

So, what is the bottom line of all these numbers?

We are making progress in reducing the burden of cancer in this country. We have made strides; however, we could do far better. It wouldn’t necessarily take some great new breakthrough drug or procedure, although we are making considerable progress on that front as well.

No, for many the answer isn’t necessarily the great breakthrough. It’s the everyday blocking and tackling that will continue to make a real difference: healthy lifestyles, access to accurate information (such as that found on our website at and access to care. It’s about making certain everyone has that access no matter their circumstances, no matter where they live.

If we would do that and continue our research into the causes of cancer and the development of new drugs as well as determining the best ways to use those treatments we already have, then this march towards progress will continue. If we don’t do that, then we have only ourselves and our commitment to hold accountable.




J. Leonard Lichtenfeld's Biography

Dr. Len

J. Leonard Lichtenfeld, MD, MACP: Dr. Lichtenfeld currently serves as Deputy Chief Medical Officer for the American Cancer Society in the Society's Office of the Chief Medical Officer located at the Society's Corporate Center in Atlanta. Dr. Lichtenfeld joined the Society in 2001 as a medical editor, and in 2002 assumed responsibility for managing the Society's then newly created Cancer Control Science Department which included the prevention and early detection of cancer, emerging cancer science and trends, health equity, quality of life for cancer patients, the science of cancer communications and the role of nutrition and physical activity in cancer prevention and cancer care.  In 2014, Dr. Lichtenfeld assumed his current role in the Office of the Chief Medical Officer where he provides extensive support to a number of Society colleagues and activities. As a result of his over four decades of experience in cancer care, Dr. Lichtenfeld is frequently quoted in the print and electronic media regarding the Society's positions on a number of important issues related to cancer. He has testified regularly in legislative and regulatory hearings, and participated on numerous panels regarding cancer care, research, advocacy and related topics. He has served on a number of advisory committees and boards for organizations that collaborate with the Society to reduce the burden of cancer nationally and worldwide. He is well known for his blog ( which first appeared in 2005 and which continues to address many topics related to cancer research and treatment. A board certified medical oncologist and internist who was a practicing physician for over 19 years, Dr. Lichtenfeld has long been engaged in health care policy on a local, state, and national level.  He is active in several state and national medical organizations and has a long-standing interest in professional legislative and regulatory issues related to health care including physician payment, medical care delivery systems, and health information technology. Dr. Lichtenfeld is a graduate of the University of Pennsylvania and Hahnemann Medical College (now Drexel University College of Medicine) in Philadelphia.  His postgraduate training was at Temple University Hospital in Philadelphia, Johns Hopkins University School of Medicine and the National Cancer Institute in Baltimore. He is a member of Alpha Omega Alpha, the national honor medical society.  Dr. Lichtenfeld has received several awards in recognition of his efforts on behalf of his colleagues and his professional activities.  He has been designated a Master of the American College of Physicians in acknowledgement of his contributions to internal medicine.  Dr. Lichtenfeld is married, and resides in Atlanta and Thomasville, Georgia.

Leave a Reply

Your email address will not be published. Required fields are marked *